Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pulmonary Hypertension: early-phase trial registry
37 of 73 indexed Pulmonary Hypertension trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #188 of 28,707 conditions by registered trial count.
73 US clinical trials · 37 currently recruiting · #188 of 28,707 conditions by registered trial count
Pulmonary Hypertension: 73 US clinical trials tracked, 37 recruiting.
Pulmonary Hypertension is the subject of 73 registered US clinical trials on ClinicalTrials.gov, 37 of them currently open to new participants. 11 are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most active sponsor is United Therapeutics, running 4 of these trials.
Enrollment posture brief
Registry condition pulmonary-hypertension
OPEN 37 | RECR 51% | LATE 11 | EARLY 23 | RANK #188 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Neuroendocrine Tumors (51% recruiting · 53 trials)
Pulmonary Hypertension lists 37 open slots (51% of 73 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pulmonary Hypertension on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pulmonary Hypertension is recruiting above its size-band peers.
37 of 73 indexed trials (50.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pulmonary Hypertension trials is spread across many organizations.
United Therapeutics accounts for 4 of 73 trials (5.5%). 54 distinct sponsors appear on at least one study for this condition label.
-
Typical Pulmonary Hypertension enrolment sits around 60 participants.
Median target enrolment is 60 among the 73 trials that report a genuine target (sentinel values excluded). 40 of those (54.8%) plan for fewer than 100 participants.
-
Pulmonary Hypertension splits between interventional and observational designs.
45 interventional and 28 observational studies make up this index (61.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
73 total, page 1 of 2
Rutgers University Study of the Genetics of Pulmonary Hypertension
Rutgers, The State University of New Jersey
NCT07217522
CVD/PH and Voice Characteristics
Mayo Clinic
NCT07311044
Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders
Children's Hospital Medical Center, Cincinnati
NCT07477197
Pulmonary Hypertension in Left Heart Disease
Mayo Clinic
NCT05935605
Pulmonary Hypertension Association Registry
Pulmonary Hypertension Association
NCT04071327
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
Eko Devices
NCT05873387
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
United Therapeutics
NCT06388421
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Abbott Medical Devices
NCT06526195
New Orleans Pulmonary Hypertension Biobank
Louisiana State University Health Sciences Center in New Orleans
NCT03269630
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Insmed Incorporated
NCT07179380
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
United Therapeutics
NCT05776225
Pulmonary Hypertension Biorepository and Registry
University of Kansas Medical Center
NCT04808596
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
National Institutes of Health Clinical Center (CC)
NCT01730092
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
Mario Castro, MD, MPH
NCT04624490
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
Tenax Therapeutics
NCT05983250
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
Tectonic Therapeutic
NCT06616974
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
VA Office of Research and Development
NCT05937854
Study Roles of Heavy Metals and Essential Metal Dyshomeostasis in Pulmonary Arterial Hypertension Patients
Jiapeng Huang
NCT04756076
Prospective Validation of the Novel PVD-B65 Risk Score in Patients With Chronic Lung Disease and Pulmonary Hypertension
Temple University
NCT07151768
Safety and Efficacy of FETO in CDH Phase III
Children's Hospital Medical Center, Cincinnati
NCT07187206
Xenon MRI Pulm Hypertension
Bastiaan Driehuys
NCT04991454
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
Johns Hopkins University
NCT06299436
Observational Study of Patients Undergoing Diagnostic Right Heart Catheterization
HemoCept
NCT07224906
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)
University of Utah
NCT05201144
Feto-Endoscopic Tracheal Occlusion (FETO) for Severe Congenital Diaphragmatic Hernia
Children's Hospital Medical Center, Cincinnati
NCT02986087
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
Pfizer
NCT07073820
Identifying Right Ventricular Dysfunction in COPD Through Right Heart Catheterization, Imaging and Exercise
University of Colorado, Denver
NCT05896579
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
Aria CV
NCT04555161
Evaluating Infrasonic Hemodynography
Scripps Health
NCT04636892
iTONE Trial (exercIse Training in pulmONary hypertEnsion) Exercise Program for Pediatric PH
Children's Hospital of Philadelphia
NCT05442671
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
Pulmovant
NCT07333183
Bioenergetic Effect of Pioglitazone in CLD-PH
Emory University
NCT06336798
129 Xenon Imaging in Patients Treated With Sotatercept
Bastiaan Driehuys
NCT06351345
Metformin for Pulmonary Hypertension HFpEF
University of California, San Francisco
NCT03629340
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
Paul Szabolcs
NCT03630211
Feasibility of Semaglutide in Advanced Lung Disease
University of Pennsylvania
NCT05746039
Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension
Mayo Clinic
NCT06770023
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Tempus AI
NCT06911632
Activity Monitoring in Pulmonary Hypertension
Vanderbilt University Medical Center
NCT04101630
Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass
University of Pennsylvania
NCT07132788
A Study of Mosliciguat in PH-ILD
Pulmovant
NCT06635850
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
Merck Sharp & Dohme
NCT05612035
Trans-pulmonary Biomarkers in Pulmonary Hypertension
Vanderbilt University
NCT01961232
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
Liquidia Technologies
NCT06129240
Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE
Northwell Health
NCT03581877
A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension
OrphAI Therapeutics
NCT05798923
Pediatric Ventricle Function Assessment Study
HBI Solutions
NCT06739057
A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System
GE Healthcare
NCT01076296
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
United Therapeutics
NCT00887978
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Bayer
NCT00855465
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 16 |
| Phase 3 | 7 |
| Phase 4 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Pulmonary Hypertension records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pulmonary Hypertension trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pulmonary Hypertension page
73 registered trials, 37 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 37 Pulmonary Hypertension trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- United Therapeutics sponsors the most Pulmonary Hypertension trials on record, review their full trial history before evaluating a specific study. See United Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pulmonary Hypertension condition card totals 73 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.